# APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

> **NCT03165994** · PHASE2 · COMPLETED · sponsor: **Apexigen America, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Esophageal Cancer
- GastroEsophageal Cancer

## Interventions

- **DRUG:** APX005M
- **RADIATION:** Radiation Therapy
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **PROCEDURE:** Surgical resection of tumor

## Key facts

- **NCT ID:** NCT03165994
- **Lead sponsor:** Apexigen America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-06
- **Primary completion:** 2022-11-10
- **Final completion:** 2023-02-21
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165994, "APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03165994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*